Top Research Papers on Breast Cancer

A range of treatment options reflects the complexity of breast cancer therapy today, with standard therapy options including targeted approaches such as CDK4 and CDK6 inhibitors, PI3K inhibitors, PARP inhibitors, and anti-PD-L1 immunotherapy, depending on tumour type and molecular profile.

The importance of breast adipose tissue in breast development and its involvement in breast changes happening during pregnancy, lactation and involution is discussed, with an overview on its involved in the various steps of breast cancer development and progression.

Postmenopausal women should also be offered postoperative bisphosphonates, and patients at high risk of breast cancer may be candidates for risk-reducing medications.

The article presents up-to-date information for doctors of various specialties: oncologists, surgeons, mammologists, obstetricians and gynecologists, general practitioners on the problems of modern treatment of breast cancer.

The USPSTF concludes that the current evidence is insufficient to determine the balance of benefits and harms of screening mammography in women 75 years or older and the balance of benefits and harms of supplemental screening for breast cancer with breast ultrasound or magnetic resonance imaging (MRI), regardless of breast density.

The application of nanomedicine including CRISPR nanoparticle, exosomes for the treatment of BC/TNBC and other molecular targets available such as poly (ADP-ribose) polymerase (PARP), epidermal growth factor receptor (EGFR), Vascular endothelial growth factor (VEGF), etc. for further exploration have been discussed.

Progress against breast cancer mortality could be accelerated by mitigating racial disparities through increased access to high‐quality screening and treatment via nationwide Medicaid expansion and partnerships between community stakeholders, advocacy organizations, and health systems.

The Lancet Breast Cancer Commission report shows inequities in prevention, detection, treatment, and supportive care, with many groups of people with breast cancer being systematically left behind and forgotten. This is a global error as people with breast cancer are indispensable to our culture and socioeconomic system.\nNew findings: The number of people living with metastatic breast cancer is unknown and many do not receive appropriate care. With adequate resources and a shift in attitudes, it might be possible to cure some people, treat most, alleviate the suffering of all, and abandon no ...

Breast cancer, characterized by unique epidemiological patterns and significant heterogeneity, remains one of the leading causes of malignancy-related deaths in women. The increasingly nuanced molecular subtypes of breast cancer have enhanced the comprehension and precision treatment of this disease. The mechanisms of tumorigenesis and progression of breast cancer have been central to scientific research, with investigations spanning various perspectives such as tumor stemness, intra-tumoral microbiota, and circadian rhythms. Technological advancements, particularly those integrated with artif...

An up to date overview of the biology, genetics, and histology of MBC with comparison to female breast cancers and differential diagnosis from histological mimics is provided.

It is proposed that viewing ferroPTosis-related studies from a historical angle will accelerate the development of ferroptosis-based biomarkers and therapeutic strategies in breast cancer.

Socioeconomic factors, cancer stage, tumor characteristics (size and grade), and high Charlson-Dayo score contributed to higher mortality among male patients diagnosed with breast cancer.

A review of autophagy focusing on its interplay with targeted drugs used for breast cancer treatment and its potential to enhance tumor cell death by diverse anti-cancer therapies is presented.

Progress against breast cancer could be accelerated by mitigating racial, ethnic, and social disparities through improved clinical trial representation and access to high-quality screening and treatment.

This article reviews the recent existing CAAs studies on the functions and mechanisms of adipocytes in the development of BC, including adipokine regulating, metabolic reprogramming, extracellular matrix (ECM) remodeling, microRNAs (miRNAs) and immune cell adjusting.

This review study has aimed to identify what has revealed the critical properties of Qu such as anti-inflammatory, anti-oxidant, and even its effect on proliferation, angiogenesis, or apoptosis that are considered asAnti-tumor property to enhance breast cancer treatment.

Omission of radiotherapy was associated with an increased incidence of local recurrence but had no detrimental effect on distant recurrence as the first event or overall survival among women 65 years of age or older with low-risk, hormone receptor-positive early breast cancer.

A review of studies examining the heterogeneity of CAFs in breast cancer and expression patterns of CAF markers in different subtypes of breast cancer hopes that summarizing CAF‐related studies from a historical perspective will help to accelerate the development ofCAF‐targeted therapeutic strategies for breast cancer.

The intersection between extracellular signals and the transcriptional cascade that regulates adipocyte differentiation is discussed in order to appreciate the molecular pathways that have been described to drive adipocyte dedifferentiation.

This cohort study investigates the clinicopathological characteristics and breast cancer–specific survival of patients with single hormone receptor–positive breast cancer.

IMPORTANCE: Young women with breast cancer are increasingly choosing bilateral mastectomy (BM), yet little is known about short-term and long-term physical and psychosocial well-being following surgery in this population. OBJECTIVE: To evaluate the differential associations of surgery with quality of life (QOL) and psychosocial outcomes from 1 to 5 years following diagnosis. DESIGN, SETTING, AND PARTICIPANTS: Cohort study SETTING: Multicenter, including academic and community hospitals in North America PARTICIPANTS: Women age ≤40 when diagnosed with Stage 0-3 with unilateral breast cancer betw...

The review aims to provide novel concepts for the design of nanocarriers for the delivery of anti-breast cancer drugs and the application of nano-drug delivery systems in breast cancer therapy.

Analytical validity of Ki67 IHC can be reached with careful attention to pre-analytical issues and calibrated standardized visual scoring, and further development of automated scoring might help to overcome some current limitations.

This study demonstrates that systematic PPI maps provide a useful resource in contextualizing uncharacterized mutations within signaling pathways and protein complexes within malignant and premalignant cellular contexts.

Validation of techniques to identify HER2 heterogeneity in the clinic and concurrent development of agents to effectively treat tumors with non-uniform HER2 expression is needed.

Two large trials available which support the role of partial breast irradiation in low risk breast cancer patients and multiple randomized trials have established that a sequentially applied dose to the tumor bed improves local control with the cost of worse cosmetic results.

How breast cancer treatment has changed over the years and how the current standard is based on high quality scientific research are illustrated are illustrated.

The role of PR is presented, including the genomic characteristics and pathways in breast cancer, PR and endocrine therapy, which is a valuable prognostic biomarker in Breast cancer, especially in hormone-positive breast cancer.

Breast cancer is the most common malignancy in women. Basic and translational breast cancer research relies heavily on experimental animal models. Ideally, such models for breast cancer should have commonality with human breast cancer in terms of tumor etiology, biological behavior, pathology, and response to therapeutics. This review introduces current progress in different breast cancer experimental animal models and analyzes their characteristics, advantages, disadvantages, and potential applications. Finally, we propose future research directions for breast cancer animal models.

The dominating evidence extracted from the literature points towards a high potential of radiomics in disentangling malignant from benign breast lesions, classifying BC types and grades and also in predicting treatment response and recurrence risk.

The current treatments, novel approaches such as antibody-drug conjugation systems (ADCs), nanoparticles, nanoparticles (albumin-, metal-, lipid-, polymer-, micelle-based nanoparticles), and BCSCs-based therapies are presented.

The mechanism and function of the circRNA-miRNA-mRNA axis in the occurrence and metastasis of breast cancer, and resistance to chemotherapy are focused on.

The mechanism of ER-dependent downstream signaling in BC and the role of estrogens as growth factors necessary for cancer invasion and dissemination are explored and the challenges associated with the resistance to these therapies resulting from acquired ER mutations are the critical point for the new treatment strategies’ development.

Breast cancer (BC) is a heterogeneous disease, encompassing a diverse spectrum of tumours with varying morphological, biological, and clinical phenotypes. Although tumours may show phenotypic overlap, they often display different biological behaviour and response to therapy. Advances in high-throughput molecular techniques and bioinformatics have contributed to improved understanding of BC biology and refinement of molecular taxonomy with the identification of specific molecular subclasses. Although the traditional pathological morphological classification of BC is of paramount importance and ...

To level the playing field, providers must integrate genomic predictors of disease and epidemiologic characteristics of molecular breast cancer subtypes to provide personalized risk assessment, screening, and treatment for each patient.

The histologic and molecular classifications of TNBC, the genomic alterations these different tumor types harbor, and the potential impact of these alterations on the pathogenesis of these tumors are discussed.

The underlying associations between exosomes and drug resistance of BC are summarized and exosome is proposed as a candidate biomarker in predicting and monitoring the therapeutic drug response of BC and as a potential target or carrier to reverse the drug resistant BC.

How Notch signalling controls several different hallmarks of cancer within epithelial cells with sections focussed on its roles in proliferation, apoptosis, invasion, and metastasis are covered.

Focus on new therapeutic frontier represented by immunotherapy is illustrated, with particular mention of immune checkpoint inhibitors introduction in TNBC therapy and their impact on future treatments.

It is shown that unique mRNA isoforms that govern stem cell-like phenotypes escape translational repression to drive tumor progression and chemoresistance and provide a molecular basis for therapeutic strategies aimed at overcoming drug resistance and abrogating metastasis.